碳酸司维拉姆辅助治疗尿毒症合并高磷血症效果观察

发布时间：2018-03-09 00:05

本文选题：尿毒症　切入点：维持性血液透析　出处：《山东医药》2017年26期 　论文类型：期刊论文

【摘要】：目的观察磷结合剂碳酸司维拉姆治疗尿毒症合并高磷血症的临床效果。方法选择行维持性血液透析的尿毒症合并高磷血症患者120例,随机分为观察组和对照组各60例。在常规血液透析治疗基础上,观察组给予碳酸司维拉姆1.6 g/次,3次/d,对照组给予醋酸钙1.334 g/次、3次/d。2周后抽取静脉血,应用自动生化分析仪检测血清磷、钙、甲状旁腺素、碱性磷酸酶、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、尿素氮、肌酐水平。结果治疗后两组血清磷、钙磷乘积、甲状旁腺素水平均较治疗前下降,观察组血清磷、钙磷乘积低于对照组(P均0.05)。观察组血清低密度脂蛋白胆固醇、尿素氮、肌酐水平较治疗前下降(P均0.05),对照组上述指标与治疗前比较无统计学差异(P均0.05)。观察组血清高密度脂蛋白胆固醇水平与治疗前比较无统计学差异(P0.05),对照组较治疗前明显下降(P0.05)。结论碳酸司维拉姆可在短期内降低血清磷水平,在降磷的同时还可改善血脂代谢和肾功能。
[Abstract]:Objective to observe the clinical effect of siviram carbonate, a phosphate binding agent, in the treatment of uremia complicated with hyperphosphatemia. Methods 120 patients with uremia complicated with hyperphosphatemia who underwent maintenance hemodialysis were selected. On the basis of routine hemodialysis treatment, the observation group was given sparviram carbonate 1.6 g / time for 3 times / d, and the control group was given calcium acetate 1.334 g / time for 3 / d, and the venous blood was taken after 2 weeks of routine hemodialysis. Serum phosphorus, calcium, parathyroid hormone, alkaline phosphatase, total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, urea nitrogen were detected by automatic biochemical analyzer. Results after treatment, the levels of serum phosphorus, calcium and phosphorus, parathyroid hormone in the two groups were decreased, the serum phosphorus and calcium phosphorus product in the observation group were lower than those in the control group (P < 0.05), and the serum low density lipoprotein cholesterol and urea nitrogen in the observation group were lower than those in the control group. The level of creatinine in the control group was lower than that before treatment (P < 0.05), but there was no significant difference in the above indexes between the control group and the control group (P < 0.05). There was no significant difference in serum high density lipoprotein cholesterol level between the observation group and the control group (P 0.05), while in the control group there was no significant difference between the two groups. Conclusion Sveram can decrease serum phosphorus level in a short period of time. It can also improve the metabolism of blood lipids and renal function while reducing phosphorus.
【作者单位】：山东大学第二医院;
【基金】：山东大学第二医院青年基金项目(Y2014010009)
【分类号】：R589.4;R692.5

【相似文献】